NAD+ fall with age is not merely a passive loss of fuel; it actively reshapes signaling through the NAD+‑consuming enzyme CD38. As NAD+ drops, CD38 shifts its catalytic balance from NAD+ hydrolysis toward production of cyclic ADP‑ribose (cADPR), a potent calcium‑mobilizing second messenger. Elevated cytosolic cADPR activates ryanodine receptors, releasing Ca2+ from the endoplasmic reticulum. This calcium surge stimulates the phosphatase calcineurin, which dephosphorylates FOXO transcription factors, allowing their nuclear entry and up‑regulation of autophagy‑ and antioxidant‑genes (e.g., LC3B, SOD2). In this view, the early phase of NAD+ decline triggers a protective CD38‑cADPR‑Ca2+‑FOXO program that enhances cellular cleanup and reduces oxidative stress—a transient adaptive response.

As damage accumulates, PARP1 consumption of NAD+ outpaces salvage, driving NAD+ lower still. At a critical threshold, cADPR production wanes because CD38 activity becomes limited by substrate availability, and calcium signaling collapses. Consequently, FOXO remains phosphorylated and cytoplasmic, autophagy declines, and senescent cells accumulate. The hypothesis predicts that the protective window correlates with measurable spikes in cADPR and nuclear FOXO in mid‑aged tissues, followed by a decline as NAD+ falls further.

Testable predictions:

1. In young‑mid aged mice (6‑12 months), pharmacological inhibition of CD38 will blunt the age‑associated rise in cADPR, reduce nuclear FOXO, and lower autophagy markers compared with vehicle controls.
2. Conversely, CD38‑null mice will show attenuated cADPR spikes, diminished FOXO activation, and earlier onset of autophagy loss despite higher baseline NAD+.
3. Supplementing NAD+ precursors (NMN) in late‑aged mice (>24 months) will not restore the cADPR‑FOXO axis if CD38 expression is concurrently silenced, indicating that NAD+ alone is insufficient without CD38‑mediated calcium signaling.

Falsification would occur if CD38 inhibition fails to alter cADPR levels, FOXO localization, or autophagy in mid‑aged animals, or if FOXO activation persists despite CD38 loss and low NAD+. Such outcomes would reframe NAD+ decline as purely detrimental, supporting the view that any apparent benefit is epiphenomenal rather than mechanistically driven.